<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dynamic hyperinflation in patients with COPD</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dynamic hyperinflation in patients with COPD</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dynamic hyperinflation in patients with COPD</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meredith C McCormack, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Umur Hatipoglu, MD, MBA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Exercise or hyperpnea-induced air trapping is referred to as dynamic hyperinflation. Patients with chronic obstructive pulmonary disease (COPD) are particularly susceptible to dynamic hyperinflation. Common questions include:</p><p class="bulletIndent1"><span class="glyph">●</span>What causes dynamic hyperinflation?</p><p class="bulletIndent1"><span class="glyph">●</span>What are its clinical manifestations?</p><p class="bulletIndent1"><span class="glyph">●</span>How is it diagnosed?</p><p class="bulletIndent1"><span class="glyph">●</span>What is the treatment?</p><p></p><p>The pathophysiology, clinical presentation, diagnosis, and treatment of dynamic hyperinflation in patients with COPD are reviewed here. The diagnosis and treatment of COPD are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1455.html" rel="external">"Chronic obstructive pulmonary disease: Diagnosis and staging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/120326.html" rel="external">"Stable COPD: Overview of management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/122160.html" rel="external">"Stable COPD: Follow-up pharmacologic management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease"</a>.)</p><p></p><p class="headingAnchor" id="H3457893375"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Two types of lung hyperinflation can be distinguished, dynamic and static:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Static hyperinflation</strong> – Static hyperinflation refers to an increase in end-expiratory lung volume (EELV) at rest. It develops over time in patients with COPD due to a combination of small airway obstruction and decreased elastic recoil pressure compared with healthy adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dynamic hyperinflation</strong> – Dynamic hyperinflation refers to an increase in EELV during hyperpnea induced by exertion, anxiety, pain, exacerbation, or mechanical ventilation in patients with airflow limitation (eg, asthma, COPD).</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>In healthy adults, end-expiratory lung volume (EELV) remains stable or decreases during exercise, despite the increase in tidal volume  (<a class="graphic graphic_figure graphicRef69862" href="/d/graphic/69862.html" rel="external">figure 1</a>), because the tidal volume is completely exhaled prior to the initiation of the next breath. In patients with COPD, EELV increases (hyperinflation) when compensatory mechanisms are insufficient to overcome airflow limitation and/or loss of elastic recoil. </p><p class="headingAnchor" id="H4"><span class="h2">Static hyperinflation</span><span class="headingEndMark"> — </span>Static hyperinflation develops at rest, most commonly in patients with COPD and occasionally in patients with chronic obstructive asthma. Normally, elastic recoil pressure declines during expiration, reaching zero at EELV. Patients with COPD have decreased elastic recoil pressure at a given lung volume (due to emphysematous loss of lung tissue) compared with healthy patients; therefore, the elastic recoil pressure falls to zero at a larger EELV  (<a class="graphic graphic_figure graphicRef63226" href="/d/graphic/63226.html" rel="external">figure 2</a>). This is referred to as static hyperinflation, which exists at rest.</p><p class="headingAnchor" id="H5"><span class="h2">Dynamic hyperinflation</span><span class="headingEndMark"> — </span>Dynamic hyperinflation occurs when airflow limitation prevents complete exhalation and results in an increase in EELV, usually in the setting of the increased minute ventilation associated with exercise or other causes of hyperpnea. Hyperinflation generally acts as a compensatory mechanism; at higher lung volumes, airway resistance decreases and elastic recoil increases, resulting in improved expiratory flow.</p><p>However, in the setting of airflow limitation, hyperinflation can have a negative impact. During exertion, individuals with COPD recruit expiratory muscles to increase pleural and alveolar pressures in an effort to increase expiratory flow and completely exhale the increased tidal volume prior to the next breath. However, the airways of patients with COPD typically compress or collapse when the pleural pressure is positive, thereby preventing increased expiratory flow [<a href="#rid1">1,2</a>]. As a result, exhalation may not be completed prior to the onset of the next breath, causing progressive hyperinflation  (<a class="graphic graphic_figure graphicRef63226" href="/d/graphic/63226.html" rel="external">figure 2</a>) [<a href="#rid3">3,4</a>]. This is referred to as dynamic hyperinflation; it occurs during exercise and can exist in the presence or absence of static hyperinflation [<a href="#rid5">5-7</a>].</p><p>Dynamic hyperinflation limits ventilation during exercise and can negatively impact cardiac function [<a href="#rid8">8-12</a>]. The increase in EELV can lead to increased end-expiratory pressure, which in turn can decrease venous return, compromising cardiac output. Studies that demonstrate improvement in cardiac function after interventions to reduce dynamic hyperinflation, such as lung volume reduction surgery, support this concept [<a href="#rid13">13-17</a>]. Similarly, reducing minute ventilation can help restore cardiac output in patients with asthma or COPD who develop hypotension due to dynamic hyperinflation during mechanical ventilation. (See  <a class="medical medical_review" href="/d/html/570.html" rel="external">"Invasive mechanical ventilation in adults with acute exacerbations of asthma", section on 'Dynamic hyperinflation'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL PRESENTATION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>During exertion</strong> – The cardinal symptom of dynamic hyperinflation is dyspnea on exertion. Although hyperinflation is a compensatory mechanism that increases expiratory flow, it increases the work of breathing, places the inspiratory muscles at a mechanical disadvantage due to length-tension effects, and produces a positive alveolar pressure that must be overcome to initiate a breath [<a href="#rid18">18,19</a>]. The net effect is a marked disparity between the level of inspiratory effort (approaches maximum) and the actual mechanical response of the respiratory system (greatly diminished tidal volume), which manifests as dyspnea, initially with exertion and later at rest.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>During mechanical ventilation</strong> – Dynamic hyperventilation can also develop during mechanical ventilation in patients with asthma or COPD when the expiratory time is insufficient to completely exhale the tidal volume, leading to breath stacking. In this setting, dynamic hyperinflation can present as ventilator dyssynchrony, elevated plateau pressure at end-inspiration, hypotension, and sometimes pneumothorax. When dynamic hyperinflation occurs, ventilator graphics will typically reveal commencement of inspiratory flow before expiratory flow reaches zero and a progressive rise in peak airway pressures during mandatory volume-targeted ventilation. (See  <a class="medical medical_review" href="/d/html/1632.html" rel="external">"Invasive mechanical ventilation in acute respiratory failure complicating chronic obstructive pulmonary disease", section on 'Dynamic hyperinflation'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Dynamic hyperinflation may be suspected in patients with COPD who experience dyspnea on exertion, particularly when dyspnea seems more severe than would be suggested by spirometry. The occurrence of dynamic hyperinflation is not clearly predicted by the severity of COPD (based on the reduction in forced expiratory volume in one second), as patients with the most severe COPD tend to have less dynamic hyperinflation [<a href="#rid20">20</a>]. It is possible that the degree of baseline hyperinflation in severe COPD inhibits further dynamic hyperinflation. We evaluate for dynamic hyperinflation when the cause of dyspnea is unclear and identifying the cause of dyspnea will enable specific treatment and avoid unnecessary treatments. </p><p>Definitive diagnosis of dynamic hyperinflation requires measurement of end-expiratory lung volume (EELV) during exercise. This is time consuming, labor intensive, and technically difficult. Therefore, these indirect measures obtained before and after exercise are more common: measurement of inspiratory capacity (decreases with dynamic hyperinflation) and comparison of flow-volume loops. </p><p class="headingAnchor" id="H8"><span class="h2">Decreased inspiratory capacity with exertion</span><span class="headingEndMark"> — </span>Hyperinflation is defined as an elevated EELV. Decreased inspiratory capacity (IC) is used as a surrogate measure of increased EELV. This is based upon the assumption that total lung capacity (TLC) is constant; therefore, an increase of the EELV must be accompanied by a decrease of the IC since the sum of the two measures is the total lung capacity (ie, EELV + IC = TLC) [<a href="#rid21">21,22</a>].</p><p>During exercise, healthy individuals increase their tidal volume. To ensure that the entire tidal volume is exhaled prior to their next breath, they recruit expiratory muscles and increase their expiratory flow, which results in an increased IC and decreased EELV. In contrast, patients with COPD are unable to sufficiently increase their expiratory flow and completely exhale the increased tidal volume prior to the next breath; as a result, the IC decreases and the EELV increases during exercise  (<a class="graphic graphic_figure graphicRef63226" href="/d/graphic/63226.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef77593" href="/d/graphic/77593.html" rel="external">figure 3</a>). Progressive decrease of IC during exercise is highly suggestive of dynamic hyperinflation.</p><p>In an observational study of 22 subjects with moderately severe COPD, inspiratory capacity was monitored every two minutes during a six-minute walk test [<a href="#rid23">23</a>]. During the first two minutes of the test, tidal volume increased, suggesting that dyspnea during that time frame was due to increased respiratory effort. Subsequently, the increase in dyspnea correlated with a progressive decrease in inspiratory capacity without further increase in tidal volume, suggesting that dynamic hyperinflation contributed to dyspnea.</p><p class="headingAnchor" id="H9"><span class="h2">Exercise flow-volume loop encroaching on maximal flow-volume loop</span><span class="headingEndMark"> — </span>Another method compares the maximal flow-volume loop (MFVL) versus the tidal flow-volume loop during exercise (extFVL), such as during a six-minute walk test or cardiopulmonary exercise test [<a href="#rid4">4</a>]. In healthy individuals, the extFVL and the MFVL are distinct, whereas the flow-volume loops become increasingly similar (ie, there is encroachment of the extFVL on the MFVL) with an increasing EELV as dynamic hyperinflation progresses  (<a class="graphic graphic_figure graphicRef63226" href="/d/graphic/63226.html" rel="external">figure 2</a>).</p><p>The MFVL is obtained by spirometry with the patient resting prior to exercise, while the extFVL is obtained at several different work intensities during exercise. Either a single representative extFVL or the mean of two or more extFLVs is plotted within the largest MFVL  (<a class="graphic graphic_figure graphicRef63226" href="/d/graphic/63226.html" rel="external">figure 2</a>) [<a href="#rid24">24-27</a>]. Since bronchodilation or bronchoconstriction may occur during exercise, additional MFVLs are often obtained during or immediately after exercise. IC is also determined during rest and exercise, and then used to correctly align the extFVL within the MFVL.</p><p class="headingAnchor" id="H394093185"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Dyspnea on exertion cannot be assumed to be due to dynamic hyperinflation, as patients with COPD may have dyspnea due to other processes related to COPD, including the following [<a href="#rid28">28,29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dynamic airway compression due to increased pleural pressure during exhalation.</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory and skeletal muscle weakness/fatigue due to chronic disease and possibly systemic glucocorticoid use.</p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical disadvantage of diaphragm caused by hyperinflation.</p><p class="bulletIndent1"><span class="glyph">●</span>Increased ventilatory demand due to airflow limitation, increased physiologic dead space, hypoxemia (eg, due to secondary pulmonary hypertension or severe emphysema), hypercapnia, early-onset lactic acidosis, or deconditioning.</p><p></p><p>In addition, comorbidities related to COPD may be contributory, such as coronary heart disease, heart failure (with or without preserved ejection fraction), deconditioning, and fatigue. (See  <a class="medical medical_review" href="/d/html/1439.html" rel="external">"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions", section on 'Comorbid diseases'</a> and  <a class="medical medical_review" href="/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Assessment of the patient with refractory COPD'</a> and  <a class="medical medical_review" href="/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Evaluating for comorbid diseases'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The mainstay of treatment for dynamic hyperinflation during exertion is bronchodilation; additional steps may include decreasing ventilatory load. Small decreases in end-expiratory lung volume (EELV) are often associated with substantial clinical improvement, suggesting that hyperinflation is an important cause of dyspnea. Reduction of hyperinflation can be achieved by multiple approaches, and combination treatments have been shown to have additive benefits, as described below [<a href="#rid30">30</a>].</p><p>Changes in inspiratory capacity (IC) during maximal exercise have been used in clinical trials to test the efficacy of interventions in reducing dynamic hyperinflation. A mean minimally important difference of 0.2 liters has been proposed for change in IC during exercise [<a href="#rid31">31</a>]. This has been used in clinical trials of bronchoscopic lung volume reduction (BLVR) to construct responders analyses [<a href="#rid32">32</a>].</p><p>Studies of interventions to improve dynamic hyperinflation suggest that clinical improvement results from not only respiratory mechanics but also improvements in cardiac [<a href="#rid33">33</a>] function [<a href="#rid13">13-15</a>]. (See  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p class="headingAnchor" id="H2347663763"><span class="h2">Decrease airflow obstruction</span><span class="headingEndMark"> — </span>Long-acting bronchodilators reduce dynamic hyperinflation at rest and during exercise, resulting in improved exercise capacity and reduced dyspnea on exertion. A systematic review of long-acting bronchodilators in COPD included a meta-analysis of the effects of monotherapy with long-acting muscarinic antagonists or long-acting beta agonists on exercise capacity. With treatment, exercise time increased by 67 seconds (95% CI 55-79 seconds), inspiratory capacity during exercise increased by 196 mL (95% CI 162-229 mL), and dyspnea improved with a change of -0.41 units (-0.56 to -0.27) on the Borg scale [<a href="#rid34">34</a>]. </p><p class="headingAnchor" id="H11"><span class="h3">Long-acting muscarinic antagonists</span><span class="headingEndMark"> — </span>Long-acting muscarinic antagonists (LAMAs) produce sustained reductions in hyperinflation during rest and exercise, resulting in improved exercise capacity and reduced dyspnea with exertion [<a href="#rid34">34,35</a>]. This was illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a crossover study, 29 patients with stable COPD performed spirometry and exercise before and one hour after receiving nebulized <a class="drug drug_general" data-topicid="8570" href="/d/drug information/8570.html" rel="external">ipratropium</a> bromide (500 mcg) or placebo [<a href="#rid36">36</a>]. The inspiratory capacity at rest increased 14 percent following ipratropium, consistent with decreased static hyperinflation. This was accompanied by improved exercise endurance and dyspnea during exercise. There were no significant changes in spirometry, exercise endurance, or exertional dyspnea after receiving placebo. A similarly designed crossover study suggested a prolonged (six-hour) reduction in static hyperinflation (residual volume [RV]) after nebulized LAMA treatment [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A parallel-group trial randomly assigned 187 patients with COPD to receive <a class="drug drug_general" data-topicid="10300" href="/d/drug information/10300.html" rel="external">tiotropium</a> (18 mcg) or placebo once daily for 42 days [<a href="#rid35">35</a>]. Spirometry, plethysmographic lung volumes, exercise endurance, and exertional dyspnea of the tiotropium group were compared with the placebo group. Tiotropium increased the inspiratory capacity and decreased the end-expiratory lung volume at rest, consistent with decreased static hyperinflation. In addition, tiotropium increased exercise capacity and improved exertional dyspnea. These findings were supported by a subsequent randomized trial in 261 COPD patients that demonstrated that tiotropium reduces hyperinflation at rest and with exercise and improves symptom-limited exercise tolerance after six weeks of treatment. In this study, improvement with tiotropium versus placebo was demonstrated at two hours and eight hours after dosing [<a href="#rid38">38</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 181 participants with moderate-to-severe COPD were assigned to once-daily <a class="drug drug_general" data-topicid="86043" href="/d/drug information/86043.html" rel="external">aclidinium</a> 200 mcg or placebo for six weeks [<a href="#rid39">39</a>]. Aclidinium treatment improved exercise tolerance and reduced static hyperinflation. </p><p></p><p class="headingAnchor" id="H12"><span class="h3">Long-acting beta-agonists</span><span class="headingEndMark"> — </span>Long-acting beta-agonists (LABAs) similarly decrease static hyperinflation, allowing greater dynamic hyperinflation during exercise before intolerable dyspnea develops [<a href="#rid34">34,40,41</a>]. This was illustrated by a crossover study that randomly assigned 23 patients with COPD to receive <a class="drug drug_general" data-topicid="9875" href="/d/drug information/9875.html" rel="external">salmeterol</a> (50 mcg) or placebo twice daily for two weeks and then compared spirometry and exercise capacity in the salmeterol group versus the placebo group [<a href="#rid40">40</a>]. Salmeterol increased the inspiratory capacity during rest and exercise, consistent with decreased static and dynamic hyperinflation. It also increased exercise endurance and decreased dyspnea during exercise. In a study of 21 individuals with advanced GOLD III-IV COPD, <a class="drug drug_general" data-topicid="8946" href="/d/drug information/8946.html" rel="external">formoterol</a> was associated with improvement in exercise tolerance and dynamic hyperinflation compared with placebo [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H3100963222"><span class="h3">Combination LAMA and LABA</span><span class="headingEndMark"> — </span>Combination LAMA-LABA therapy has been shown to reduce hyperinflation before and during exercise in two randomized, replicate crossover trials of <a class="drug drug_general" data-topicid="10300" href="/d/drug information/10300.html" rel="external">tiotropium</a>/<a class="drug drug_general" data-topicid="96482" href="/d/drug information/96482.html" rel="external">olodaterol</a> combination therapy versus monotherapy with either component or placebo [<a href="#rid43">43</a>]. Combination therapy also yielded improvements in dyspnea and exercise tolerance versus placebo. Two randomized crossover studies of <a class="drug drug_general" data-topicid="95147" href="/d/drug information/95147.html" rel="external">umeclidinium</a>/vilanterol demonstrated that combination therapy was associated with improvement in forced expiratory volume in one second (FEV<sub>1</sub>) and exercise capacity [<a href="#rid44">44</a>]. </p><p class="headingAnchor" id="H13"><span class="h3">Combination beta-agonist and inhaled glucocorticoid</span><span class="headingEndMark"> — </span>Combined long-acting beta-agonist plus inhaled glucocorticoid decreases hyperinflation and improves exercise endurance. This was illustrated in a trial of 185 patients with COPD who were randomly assigned to receive placebo, <a class="drug drug_general" data-topicid="9875" href="/d/drug information/9875.html" rel="external">salmeterol</a> alone (50 mcg), or <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a> (250 mcg) plus salmeterol (50 mcg) twice daily for eight weeks [<a href="#rid45">45</a>]. Compared with placebo, combination therapy increased the inspiratory capacity during rest and exercise, consistent with decreased static and dynamic hyperinflation. It also increased exercise endurance. Static hyperinflation was the only outcome for which combination therapy and salmeterol were compared, with combination therapy demonstrating a greater impact.</p><p>Inhaled glucocorticoids alone enhance bronchodilator-mediated improvement of dyspnea [<a href="#rid46">46</a>]. However, it is unknown whether this observation is due to improvement in dynamic hyperinflation. Monotherapy with inhaled glucocorticoids is not recommended for COPD. </p><p class="headingAnchor" id="H1938864832"><span class="h2">Reduce ventilatory load</span><span class="headingEndMark"> — </span>One way to reduce dynamic hyperinflation is to decrease the ventilatory drive, which reduces the respiratory rate and prolongs expiratory time. Supplemental oxygen may decrease both the metabolic demand at a given workload and also influence the neural drive to breathe. Pulmonary rehabilitation and exercise training at submaximal intensities can improve endurance and reduce the ventilatory demand for a given level of exercise. </p><p class="headingAnchor" id="H4009144740"><span class="h3">Oxygen</span><span class="headingEndMark"> — </span>Supplemental oxygen therapy is well known to be beneficial in patients with COPD and hypoxemia. It also appears to decrease dynamic hyperinflation by decreasing ventilatory demand, even in patients who are not hypoxemic with exercise [<a href="#rid30">30</a>]. This was best illustrated by an observational study of 10 patients with COPD who underwent spirometry and exercise testing while receiving different concentrations of oxygen [<a href="#rid47">47</a>]. Compared with room air, hyperinflation was progressively reduced when breathing 30 and 50 percent oxygen. There was no additional reduction of hyperinflation when the patients breathed 75 or 100 percent oxygen. Similarly, a randomized trial demonstrated faster resolution of dynamic hyperinflation following exercise among patients who received oxygen [<a href="#rid48">48</a>]. While of interest in a research setting, supplemental oxygen at these levels carries the risk of hypercapnia and is not advised for this indication.</p><p class="headingAnchor" id="H1951508825"><span class="h3">Pulmonary rehabilitation</span><span class="headingEndMark"> — </span>Rehabilitative exercise training generally yields the greatest improvement in exercise tolerance [<a href="#rid30">30</a>]. At least part of this improved exercise capacity is due to reduced dynamic hyperinflation.</p><p>An observational study evaluated dynamic hyperinflation in 24 patients with COPD following a seven-week training program [<a href="#rid49">49</a>]. Inspiratory capacity dropped less precipitously, and exercise capacity increased following the training program, suggesting that dynamic hyperinflation was less, although still present. (See  <a class="medical medical_review" href="/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a>.)</p><p class="headingAnchor" id="H3751440659"><span class="h3">Positive expiratory pressure</span><span class="headingEndMark"> — </span>Provision of positive expiratory pressure (PEP) decreases inspiratory muscle work required to breathe at high lung volumes, which may reduce dyspnea, leading to beneficial effects on respiratory rate and therefore dynamic hyperinflation itself.</p><p>In a randomized double-blind crossover trial, 19 patients with severe COPD performed constant work rate endurance cycle tests in random order with no noninvasive ventilation (NIV), NIV with individually titrated expiratory positive airway pressure (T–EPAP), and NIV with standardized EPAP of 5 cm H<sub>2</sub>O (S–EPAP) [<a href="#rid50">50</a>]. Use of NIV (both S-EPAP and T-EPAP) reduced dynamic hyperinflation (improved exercise IC) and improved endurance time.</p><p>A separate cross-over study of 20 subjects found that nasal-PEP during exercise reduced postexercise lung volumes and increased six-minute walk distance, suggesting an impact on dynamic hyperinflation [<a href="#rid51">51</a>].</p><p>Further study is needed to determine whether PEP can enhance endurance training and longer-term exercise capacity in patients with COPD.</p><p class="headingAnchor" id="H20"><span class="h2">Lung volume reduction</span><span class="headingEndMark"> — </span>Lung volume reduction can be performed surgically (LVRS) or bronchoscopically (BLVR). (See  <a class="medical medical_review" href="/d/html/1430.html" rel="external">"Lung volume reduction surgery in COPD"</a> and  <a class="medical medical_review" href="/d/html/14862.html" rel="external">"Bronchoscopic treatment of emphysema"</a>.)</p><p class="headingAnchor" id="H21"><span class="h3">Surgical</span><span class="headingEndMark"> — </span>Dyspnea relief following LVRS has also been shown to correlate well with reduced dynamic hyperinflation [<a href="#rid52">52,53</a>].</p><div class="formulaContainer"><div class="formula"><p>The effect of LVRS on dynamic hyperinflation was studied in a series of 42 patients with severe, upper-lobe predominant emphysema with hyperinflation (total lung capacity [TLC] mean 125 percent predicted) and air trapping (RV mean 198 percent predicted) who underwent LVRS [<a href="#rid54">54</a>]. Postbronchodilator TLC was measured at each visit (prior to surgery and at 6, 12, 24, and 36 months). During a symptom-limited cardiopulmonary exercise test (CPET), IC was measured every two minutes and end-expiratory lung volume (EELV) was calculated (EELV = TLC – IC). The main measure of DH was the EELV/TLC ratio. Compared with the post-rehab (pre-LVRS) baseline, dynamic hyperinflation was significantly reduced at 6, 12, 24, and 36 months after LVRS. Patients adopted a slower, deeper breathing pattern during exercise after LVRS, which strongly correlated with reductions in DH. Thus, improvements in dynamic hyperinflation appear to be durable for up to three years after LVRS. </p></div></div><p class="headingAnchor" id="H22"><span class="h3">Bronchoscopic</span><span class="headingEndMark"> — </span>BLVR also reduces the volume of highly emphysematous lung that contributes to prolonged expiratory time and dynamic hyperinflation. (See  <a class="medical medical_review" href="/d/html/14862.html" rel="external">"Bronchoscopic treatment of emphysema"</a>.)</p><p>Since the more widespread use of endobronchial valves following their regulatory approval, there have been an increasing number of clinical trials demonstrating a reduction in hyperinflation at rest and increase in exercise tolerance [<a href="#rid55">55</a>]. These measures have also shown improvements after some investigational BLVR techniques. A few studies have directly assessed dynamic hyperinflation more directly:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, 19 COPD patients were evaluated before and four weeks after endobronchial valve placement [<a href="#rid56">56</a>]. Indices of both static hyperinflation (functional residual capacity) and dynamic hyperinflation (EELV at peak exercise) improved following the procedure, as did cycle endurance time. Logistic regression analysis suggested that postprocedural changes in resting IC and transfer factor explained a large majority of the improvement in endurance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate study of 11 patients who received endobronchial coils and 11 patients with similarly severe COPD who did not, BLVR treatment led to increased endurance time as well as increased IC at rest and during exercise, suggesting improved static and dynamic hyperinflation [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of 39 patients with severe emphysema were assessed before and three months after BLVR. The primary endpoint was the mean change in IC at isotime, which was defined as the final 30 second period of exercise achieved on the shortest of the two incremental cycle ergometry tests. IC improved significantly (mean improvement of 214 mL) and 18 of 38 patients who demonstrated dynamic hyperinflation at baseline demonstrated improvement greater than the minimal clinically important difference (MCID) of 200 mL [<a href="#rid32">32</a>]. The investigators suggest that further studies are needed to assess criteria related to static and dynamic hyperinflation in selecting candidates for BLVR [<a href="#rid32">32,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, another study using different techniques to measure dynamic hyperinflation found a different result. In this study, 18 patients who underwent BLVR and 13 patients with severe COPD who received standard of care were evaluated for dynamic hyperinflation using IC measurement before and after a manually paced tachypnea test (MPT) [<a href="#rid59">59</a>]. Compared with measurements made six months earlier, patients who had received interim BLVR demonstrated a 225 mL decrease in post-MPT IC, while there was no significant change in the control group. This increase in dynamic hyperinflation was significantly correlated with a decrease in RV (ie, improved static hyperinflation). The finding of increased dynamic hyperinflation after BLVR is seemingly at odds with the prior studies. However, it is physiologically plausible that at the high respiratory rates used during the MPT (RR ~40), the patients with severe COPD treated with BLVR achieved greater dynamic hyperinflation due to improvement in static hyperinflation (ie, improved lung volumes at rest). These findings suggest that assessment of dynamic hyperinflation requires careful interpretation in such highly obstructed patients.</p><p></p><p class="headingAnchor" id="H1825304698"><span class="h2">Therapies of unclear benefit</span><span class="headingEndMark"> — </span>Some therapies can reduce dynamic hyperinflation but are not used clinically for this purpose. As examples, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> use has declined due to improved bronchodilation and fewer adverse effects with LAMAs and LABAs; heliox has limited availability; oral <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (NAC) confers minimal benefit; and inhaled NAC has potential adverse effects.</p><p class="headingAnchor" id="H2657716943"><span class="h3">Theophylline</span><span class="headingEndMark"> — </span>While uncommonly used for this purpose, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> decreases hyperinflation and increases exercise capacity in a dose-dependent fashion [<a href="#rid60">60</a>]. As an example, in a randomized trial, 38 patients with COPD received placebo, low-dose, medium-dose, or high-dose theophylline consecutively for two months each [<a href="#rid60">60</a>]. Spirometry, lung volumes, and exercise were performed at the end of each two-month treatment period. There was a dose dependent decrease in lung volumes and increase in exercise capacity, accompanied by a modest improvement in dyspnea. An effect of theophylline to improve respiratory muscle function has also been hypothesized. (See  <a class="medical medical_review" href="/d/html/112250.html" rel="external">"Management of refractory chronic obstructive pulmonary disease", section on 'Theophylline, monitored by drug levels'</a>.)</p><p class="headingAnchor" id="H2251683894"><span class="h3">Heliox</span><span class="headingEndMark"> — </span>Another approach to reducing airflow limitation is to decrease the density of gas exhaled through obstructed airways, as occurs when breathing a mixture of helium and oxygen (heliox). While heliox is not available for routine use during exercise, study of its effects adds to our understanding of dynamic hyperinflation. The addition of helium decreases turbulence within medium and large airways and increases expiratory flow. </p><p>As an example, a crossover trial randomly assigned 10 patients to breathe room air (ie, 21 percent oxygen), hyperoxic air (40 percent oxygen), normoxic helium (21 percent oxygen plus 79 percent helium), or hyperoxic helium (40 percent oxygen plus 60 percent helium) [<a href="#rid61">61</a>]. All three gases improved exercise duration and dyspnea compared with room air, although only the helium-containing gases improved the inspiratory capacity during exercise (ie, decreased dynamic hyperinflation). (See  <a class="medical medical_review" href="/d/html/541.html" rel="external">"Physiology and clinical use of heliox"</a>.)</p><p class="headingAnchor" id="H3781582613"><span class="h3">N-acetylcysteine</span><span class="headingEndMark"> — </span>The antioxidant agent NAC has mucolytic properties when administered by nebulizer. However, nebulized NAC can cause bronchospasm, so oral preparations have been assessed for use in COPD. (See  <a class="medical medical_review" href="/d/html/1456.html" rel="external">"Role of mucoactive agents and secretion clearance techniques in COPD", section on 'N-acetylcysteine (NAC)'</a>.)</p><p>The effect of oral NAC on lung hyperinflation at rest and after exercise was examined in 24 patients with moderate to severe COPD (FEV<sub>1</sub> &lt;70 percent of predicted, FEV<sub>1</sub>/forced vital capacity [FVC] ratio &lt;0.7, functional residual capacity &gt;120 percent of predicted) [<a href="#rid62">62</a>]. Patients were randomly assigned to placebo or NAC 1200 mg/day for six weeks, followed by a two-week washout period, and then a cross over to alternate therapy for six weeks. Based on increases in IC, FVC, and endurance with NAC, NAC treatment appeared to reduce dynamic hyperinflation, probably due to a reduction in air trapping. However, routine long-term use of oral <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">acetylcysteine</a> is not recommended for COPD because of the minimal potential therapeutic benefit, the inconvenience of therapy, and potential adverse effects. (See  <a class="medical medical_review" href="/d/html/1456.html" rel="external">"Role of mucoactive agents and secretion clearance techniques in COPD", section on 'N-acetylcysteine (NAC)'</a>.)</p><p class="headingAnchor" id="H3390743157"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Chronic obstructive pulmonary disease (COPD) is the most common disease in which hyperinflation occurs. Static hyperinflation exists at rest and is predominantly due to decreased elastic recoil. Dynamic hyperinflation is induced by exercise and is primarily due to impaired expiratory flow. Dynamic hyperinflation may occur in the absence of static hyperinflation. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Dyspnea with exertion is the most common manifestation of dynamic hyperinflation. Dynamic hyperinflation can also occur during hyperpnea from other causes, such as an exacerbation of COPD, anxiety, pain, or mechanical ventilation. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Dynamic hyperinflation may be suspected in patients with COPD who experience dyspnea on exertion, particularly when dyspnea seems more severe than would be suggested by spirometry. We evaluate for dynamic hyperinflation when the cause of dyspnea is unclear and identifying the cause of dyspnea will enable specific treatment and avoid unnecessary treatments. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Direct diagnosis of dynamic hyperinflation requires lung volume measurements during exercise. Due to the technical difficulties of measuring lung volumes during exercise, spirometric techniques are more commonly used. Progressive decrease of the inspiratory capacity during exercise, and/or similarity of the exercise and maximal flow-volume loops suggest dynamic hyperinflation. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Therapies commonly used in the management of COPD, such as long-acting muscarinic antagonists (LAMAs), long-acting beta agonists (LABAs), and inhaled glucocorticoids, reduce airflow limitation and thereby improve static and/or dynamic hyperinflation. </p><p></p><p class="bulletIndent1">Therapies to reduce ventilatory demand, such as supplemental oxygen and pulmonary rehabilitation, also decrease dynamic hyperinflation. For patients with advanced COPD, lung volume reduction may improve exercise tolerance by decreasing static and dynamic hyperinflation. (See  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a> and <a class="local">'Decrease airflow obstruction'</a> above and <a class="local">'Reduce ventilatory load'</a> above.)</p><p></p><p class="headingAnchor" id="H3797235363"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Martin Kohlhäufl, MD, PhD who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">MacNee W. Pathophysiology of acute exacerbations of chronic obstructive pulmonary disease. In: Acute exacerbations of chronic obstructive pulmonary disease. Lung Biology in Health and Disease, vol 183, Siafakas NM, Anthonisen NR, Georgopoulos D (Eds), 2004. p.29.</li><li><a class="nounderline abstract_t">Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269.</a></li><li><a class="nounderline abstract_t">Milic-Emili J. Dynamic pulmonary hyperinflation and intrinsic PEEP: consequences and management in patients with chronic obstructive pulmonary disease. Recenti Prog Med 1990; 81:733.</a></li><li><a class="nounderline abstract_t">Johnson BD, Beck KC, Zeballos RJ, Weisman IM. Advances in pulmonary laboratory testing. Chest 1999; 116:1377.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 2006; 15:61.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007; 4:225.</a></li><li><a class="nounderline abstract_t">O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:180.</a></li><li><a class="nounderline abstract_t">Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med 2015; 109:785.</a></li><li><a class="nounderline abstract_t">Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J 2008; 32:1275.</a></li><li><a class="nounderline abstract_t">Tzani P, Aiello M, Elia D, et al. Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients. Respir Res 2011; 12:150.</a></li><li><a class="nounderline abstract_t">Butler J, Schrijen F, Henriquez A, et al. Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 138:350.</a></li><li><a class="nounderline abstract_t">Frazão M, Silva PE, Frazão W, et al. Dynamic Hyperinflation Impairs Cardiac Performance During Exercise in COPD. J Cardiopulm Rehabil Prev 2019; 39:187.</a></li><li><a class="nounderline abstract_t">Nasis I, Kortianou E, Vasilopoulou Μ, et al. Hemodynamic effects of high intensity interval training in COPD patients exhibiting exercise-induced dynamic hyperinflation. Respir Physiol Neurobiol 2015; 217:8.</a></li><li><a class="nounderline abstract_t">Laveneziana P, Valli G, Onorati P, et al. Effect of heliox on heart rate kinetics and dynamic hyperinflation during high-intensity exercise in COPD. Eur J Appl Physiol 2011; 111:225.</a></li><li><a class="nounderline abstract_t">Chiappa GR, Queiroga F Jr, Meda E, et al. Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179:1004.</a></li><li><a class="nounderline abstract_t">Jörgensen K, Müller MF, Nel J, et al. Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest 2007; 131:1050.</a></li><li><a class="nounderline abstract_t">Jörgensen K, Houltz E, Westfelt U, et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest 2003; 124:1863.</a></li><li><a class="nounderline abstract_t">Decramer M. Respiratory muscle interaction during acute and chronic hyperinflation. Monaldi Arch Chest Dis 1993; 48:483.</a></li><li><a class="nounderline abstract_t">Soffler MI, Hayes MM, Schwartzstein RM. Respiratory Sensations in Dynamic Hyperinflation: Physiological and Clinical Applications. Respir Care 2017; 62:1212.</a></li><li><a class="nounderline abstract_t">Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter? Chest 2010; 137:1116.</a></li><li><a class="nounderline abstract_t">Calverley PM, Koulouris NG. Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology. Eur Respir J 2005; 25:186.</a></li><li><a class="nounderline abstract_t">Younes M, Kivinen G. Respiratory mechanics and breathing pattern during and following maximal exercise. J Appl Physiol Respir Environ Exerc Physiol 1984; 57:1773.</a></li><li><a class="nounderline abstract_t">Satake M, Shioya T, Uemura S, et al. Dynamic hyperinflation and dyspnea during the 6-minute walk test in stable chronic obstructive pulmonary disease patients. Int J Chron Obstruct Pulmon Dis 2015; 10:153.</a></li><li><a class="nounderline abstract_t">Johnson BD, Reddan WG, Seow KC, Dempsey JA. Mechanical constraints on exercise hyperpnea in a fit aging population. Am Rev Respir Dis 1991; 143:968.</a></li><li><a class="nounderline abstract_t">Johnson BD, Saupe KW, Dempsey JA. Mechanical constraints on exercise hyperpnea in endurance athletes. J Appl Physiol (1985) 1992; 73:874.</a></li><li><a class="nounderline abstract_t">Babb TG, Viggiano R, Hurley B, et al. Effect of mild-to-moderate airflow limitation on exercise capacity. J Appl Physiol (1985) 1991; 70:223.</a></li><li><a class="nounderline abstract_t">Johnson BD, Scanlon PD, Beck KC. Regulation of ventilatory capacity during exercise in asthmatics. J Appl Physiol (1985) 1995; 79:892.</a></li><li><a class="nounderline abstract_t">Mahler DA. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:234.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Milne KM, James MD, et al. Dyspnea in COPD: New Mechanistic Insights and Management Implications. Adv Ther 2020; 37:41.</a></li><li><a class="nounderline abstract_t">Casaburi R, Porszasz J. Reduction of hyperinflation by pharmacologic and other interventions. Proc Am Thorac Soc 2006; 3:185.</a></li><li><a class="nounderline abstract_t">Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J 2016; 47:429.</a></li><li><a class="nounderline abstract_t">Fumat R, Dupuis M, Mallah S, et al. Impact of bronchoscopic lung volume reduction with endobronchial valves on dynamic hyperinflation: Results from the PIERCE study. Respirology 2023; 28:525.</a></li><li><a class="nounderline abstract_t">van der Molen MC, Hartman JE, Vanfleteren LEGW, et al. Reduction of Lung Hyperinflation Improves Cardiac Preload, Contractility, and Output in Emphysema: A Clinical Trial in Patients Who Received Endobronchial Valves. Am J Respir Crit Care Med 2022; 206:704.</a></li><li><a class="nounderline abstract_t">Di Marco F, Sotgiu G, Santus P, et al. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res 2018; 19:18.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:542.</a></li><li><a class="nounderline abstract_t">Siler TM, Hohenwarter C, Xiong K, et al. Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD. Pulm Ther 2021; 7:503.</a></li><li><a class="nounderline abstract_t">Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128:1168.</a></li><li><a class="nounderline abstract_t">Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med 2011; 105:580.</a></li><li><a class="nounderline abstract_t">Bellamy D, Hutchison DC. The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema. Br J Dis Chest 1981; 75:190.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24:86.</a></li><li><a class="nounderline abstract_t">Neder JA, Fuld JP, Overend T, et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir Med 2007; 101:2056.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Casaburi R, Frith P, et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J 2017; 49.</a></li><li><a class="nounderline abstract_t">Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis 2014; 8:169.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130:647.</a></li><li><a class="nounderline abstract_t">Rabe KF. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies. Proc Am Thorac Soc 2006; 3:270.</a></li><li><a class="nounderline abstract_t">Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001; 18:77.</a></li><li><a class="nounderline abstract_t">Stevenson NJ, Calverley PM. Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease. Thorax 2004; 59:668.</a></li><li><a class="nounderline abstract_t">Porszasz J, Emtner M, Goto S, et al. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 2005; 128:2025.</a></li><li><a class="nounderline abstract_t">Dennis CJ, Menadue C, Schneeberger T, et al. Bilevel Noninvasive Ventilation During Exercise Reduces Dynamic Hyperinflation and Improves Cycle Endurance Time in Severe to Very Severe COPD. Chest 2021; 160:2066.</a></li><li><a class="nounderline abstract_t">Wibmer T, Rüdiger S, Heitner C, et al. Effects of nasal positive expiratory pressure on dynamic hyperinflation and 6-minute walk test in patients with COPD. Respir Care 2014; 59:699.</a></li><li><a class="nounderline abstract_t">Martinez FJ, de Oca MM, Whyte RI, et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155:1984.</a></li><li><a class="nounderline abstract_t">Laghi F, Jubran A, Topeli A, et al. Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm. Am J Respir Crit Care Med 1998; 157:475.</a></li><li><a class="nounderline abstract_t">Lammi MR, Marchetti N, Criner GJ. Reduced dynamic hyperinflation after LVRS is associated with improved exercise tolerance. Respir Med 2014; 108:1491.</a></li><li><a class="nounderline abstract_t">Herth FJF, Slebos DJ, Criner GJ, et al. Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2019. Respiration 2019; 97:548.</a></li><li><a class="nounderline abstract_t">Hopkinson NS, Toma TP, Hansell DM, et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 2005; 171:453.</a></li><li><a class="nounderline abstract_t">Makris D, Leroy S, Pradelli J, et al. Changes in dynamic lung mechanics after lung volume reduction coil treatment of severe emphysema. Thorax 2018; 73:584.</a></li><li><a class="nounderline abstract_t">Welling JBA, Slebos DJ. Dynamics of hyperinflation. Respirology 2023; 28:507.</a></li><li><a class="nounderline abstract_t">van Dijk M, Klooster K, Hartman JE, et al. Change in Dynamic Hyperinflation After Bronchoscopic Lung Volume Reduction in Patients with Emphysema. Lung 2020; 198:795.</a></li><li><a class="nounderline abstract_t">Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297:1506.</a></li><li><a class="nounderline abstract_t">Eves ND, Petersen SR, Haykowsky MJ, et al. Helium-hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:763.</a></li><li><a class="nounderline abstract_t">Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest 2009; 136:381.</a></li></ol></div><div id="topicVersionRevision">Topic 1459 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : MacNee W. Pathophysiology of acute exacerbations of chronic obstructive pulmonary disease. In: Acute exacerbations of chronic obstructive pulmonary disease. Lung Biology in Health and Disease, vol 183, Siafakas NM, Anthonisen NR, Georgopoulos D (Eds), 2004. p.29.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10911010" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2126881" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dynamic pulmonary hyperinflation and intrinsic PEEP: consequences and management in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10559103" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Advances in pulmonary laboratory testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Physiology and consequences of lung hyperinflation in COPD</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17729066" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dyspnea and activity limitation in COPD: mechanical factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16565429" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25892293" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550609" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22074289" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3195834" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31022001" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dynamic Hyperinflation Impairs Cardiac Performance During Exercise in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26112284" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hemodynamic effects of high intensity interval training in COPD patients exhibiting exercise-induced dynamic hyperinflation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20852881" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of heliox on heart rate kinetics and dynamic hyperinflation during high-intensity exercise in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299497" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Heliox improves oxygen delivery and utilization during dynamic exercise in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426209" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14605061" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8312910" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Respiratory muscle interaction during acute and chronic hyperinflation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28655742" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Respiratory Sensations in Dynamic Hyperinflation: Physiological and Clinical Applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952059" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15640341" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6511552" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Respiratory mechanics and breathing pattern during and following maximal exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25632228" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dynamic hyperinflation and dyspnea during the 6-minute walk test in stable chronic obstructive pulmonary disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024852" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mechanical constraints on exercise hyperpnea in a fit aging population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1400051" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mechanical constraints on exercise hyperpnea in endurance athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2010380" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of mild-to-moderate airflow limitation on exercise capacity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8567533" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Regulation of ventilatory capacity during exercise in asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636091" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31673990" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Dyspnea in COPD: New Mechanistic Insights and Management Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16565430" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Reduction of hyperinflation by pharmacologic and other interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797036" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36889358" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Impact of bronchoscopic lung volume reduction with endobronchial valves on dynamic hyperinflation: Results from the PIERCE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35584341" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reduction of Lung Hyperinflation Improves Cardiac Preload, Contractility, and Output in Emphysema: A Clinical Trial in Patients Who Received Endobronchial Valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368604" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15218994" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430726" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34232493" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162703" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21183326" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7023528" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15293609" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17658249" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effects of formoterol on exercise tolerance in severely disabled patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28424359" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452426" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16963658" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16636097" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11510809" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15282386" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236851" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34224690" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Bilevel Noninvasive Ventilation During Exercise Reduces Dynamic Hyperinflation and Improves Cycle Endurance Time in Severe to Very Severe COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24170913" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of nasal positive expiratory pressure on dynamic hyperinflation and 6-minute walk test in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196106" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9476861" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of lung volume reduction surgery on neuromechanical coupling of the diaphragm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135742" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Reduced dynamic hyperinflation after LVRS is associated with improved exercise tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30836374" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579725" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893857" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Changes in dynamic lung mechanics after lung volume reduction coil treatment of severe emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37039738" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dynamics of hyperinflation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32710165" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Change in Dynamic Hyperinflation After Bronchoscopic Lung Volume Reduction in Patients with Emphysema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3147048" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Dose response relation to oral theophylline in severe chronic obstructive airways disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840742" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Helium-hyperoxia, exercise, and respiratory mechanics in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447919" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
